{'fraction_non_alphanumeric': 0.04274905422446406, 'fraction_numerical': 0.04514501891551072, 'mean_word_length': 4.58128078817734, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 1, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
A clinical study of new cases of Hansen’s disease at a tertiary health care centre in post elimination era

Leprosy is a chronic infectious disease, caused by the bacillus Mycobacterium leprae. Leprosy is transmitted through droplets from the nose and mouth of an untreated person affected by the disease to their close contacts. In 2016, globally a total of 214,783 new cases were reported; over half of them were from India (135,485) alone. However, 16 other countries with pockets of high endemicity were reported. Motor and sensory disability, including damage to fingers and toes, contractures, inability to close the eyelids and blindness can occur due to delay in treatment of the disease.

inadequate active case findings, lack of inclusion of cases from private sector and presence of high stigma in the community. 1 The WHO mentioned in the enhanced global strategy for leprosy (2011)(2012)(2013)(2014)(2015)(2016) that there is loss of clinical skills in recognizing and managing leprosy and its complications, lack of interest by the young doctors to specializing in leprosy, lack of research, less political commitment as major challenges to reduce the leprosy burden. Investment in the leprosy services is now reducing among many governments, resulting in declining professional expertise and knowledge of the disease. 2

Current situation of leprosy in India
In India, the national leprosy eradication programme (NLEP) is the centrally sponsored health scheme of the ministry of health and family welfare, government of India. While the NLEP strategies and plans are formulated centrally, the programme is implemented by states and union territories (UTs). The programme is also supported by WHO, ILEP, and few other nongovernmental organizations (NGOs). Due to their efforts, from a prevalence rate of 57.8/10,000 in 1983, India has succeeded with the implementation of MDT in bringing the national prevalence down to "elimination as a public health problem" of less than 1/10,000 in December 2005 and even further down to 0.66/10,000 in 2016. In addition to achieving the national elimination target by the end of 2005, India by the end of March 2011-2012 succeeded in achieving elimination at the state level in 34 states/UTs out of the total of 36 states/UTs. Only the state of Chhattisgarh and the UT of Dadra and Nagar Haveli were yet to achieve elimination. By the end of March 2016, 551 districts (82.36%), out of the total 669 in districts, in India had a prevalence of <1/10,000 population which is the target of elimination as a public health problem. The number of districts with prevalence between 1 and 2/10,000 were 76, number of districts with prevalence between >2 and 5/10,000 were 39, and those between 5 and 10 were 2. 3 The WHO launched a 5-year global leprosy strategy 2016-2020' in April 2016 titled 'accelerating towards a leprosy-free world'.
Perhaps, for above-mentioned reasons, the strategy for years 2016-2020 is built around three pillars: (i) to strengthen government ownership, coordination, and partnership; (ii) to stop leprosy and its complications; and (iii) to stop discrimination and promote inclusion. There is a special focus on women and children, strengthening referral systems, more effective contact tracing, assessing the value of chemoprophylaxis, and monitoring drug resistance. 4 This paper discusses the current situation of leprosy in India in the context of the world and includes the successes, new initiatives, challenges, and future implications for leprosy control in India.

Aims and objectives
Aim and objectives of the study were to study the number of increasing new cases of Hansen's disease in post elimination era.

METHODS
A prospective observational study of number of new cases of leprosy presented at a department of dermatology, venereology and leprosy BMCH, Chitradurga, Karnataka, over the period of 1 and 1/2 years (18 months) from 2017 April-2018 September.
Series of 91 cases were detected, and based on the number of skin lesions and peripheral nerves involved, according to WHO classification were classified as multibacillary (MB) and paucibacillary (PB) cases and other demographical data.

Socioeconomic status
In this study 81 (89.10%) patients were from low-income group whereas 8 (8.7%) patients were from middle income group and 2 (1.8%) patients from high income group (Table 5).

Reactions
In our study 7 (7.6%) patients had type-I reaction and 13 (14.2) patients had type-II reaction as shown in the Table  7).

WHO classification
In our study 72 (79%) patients belonged to MB group and 19 (21%) patients belonged to MB group as shown in the Table 8).  5 Santaram et al found the disease is more common in age group 21-40 years. 6 Samuel et al found the disease common in 21-40 years (48%). 7 Singh et al found disease common in 21-49 years (53%). 8 Deepika et al-Out of the total of 300 leprosy patients 4% (12) patients belonged to the paediatric age group (<14 years) and the male-to-female ratio was 3:1 in children.
Family history was present in 25% of the children with leprosy. 9

Sex distribution
Out of 91 patients 51 (56%) were male, 40 (44%) were female. M:F ratio of is 1.2:1. Swarnakumari et al found 70.1% were male, 29.9% were female. 5 Santaram et al found 80% were male, 20% were female. 6 Singh et al found 69% were male, 31% were female. 8 Results of the present study are close to the abovementioned studies with male predominance.
Swarnakumari et al found more cases in BT 102 (52.57%) group, followed by LL 23 (11.85%), least in TT group 2 (1.03%) cases. 5 Jindal et al found 33% BT cases, 23% BL cases, TT 5.5% cases. 10 Arora et al found BL cases 45%, 27.5% of cases in BT, 15.5% cases in LL, 1.3% in TT group. 11 Thus, the clinical types of leprosy vary from study to study and place to place. Borderline leprosy lesions are more apparent and this may be the reason for more patients self-reporting to the hospitals.

Socioeconomic status
In this study 81 (89.10%) patients were from low-income group whereas 8 (8.7%) patients were from middle income group and 2 (1.8%) patients from high income group.
Swarnakumari et al found 80% were low-income group, 20% were middle income group. 5 Singh et al found 57% were low-income group, 21.6% were lower-middle income group. 8 Disease is highest in low socioeconomic status, person who lived in poor conditions, overcrowding, poor nutrition, poor sanitation, illiteracy and lack of personal hygiene are important factors for acquisition of leprosy disease.

Reactions
In our study 7 (7.6%) patients had type-I reaction and 13 (14.2%) patients had type-II reaction. Swarnakumari et al found 8 (4.12%) type-I lepra reaction and 10 (5.15%) type-II lepra reaction. 5 Arora et al found reactions in 34% of their study group, in that type-I is more common than type-II lepra reaction. 11 Our study is similar to Swarnakumari et al type-II reactions are common. 5

Limitations
Patients included in the present study were only those who attended the outpatient and inpatient departments of DVL of Basaveshwara medical college hospital, Chitradurga. Hence this study gives limited information about the epidemiology of the disease.
The duration of study was only one and half year. So, further studies are required to know the disease status better which helps in planning for preventive measures, early diagnosis and management.

CONCLUSION
Around 2.5 lakhs new cases are recorded each year all over the world, ranking 12 th highest cause of morbidity from neglected cases and 11 th highest cause of mortality. Perhaps we are failing to understand some important aspects of the disease's natural history. Prospect of elimination has discouraged the research in the field. There is disappointingly very little progress in the development of an effective vaccine for leprosy. We should not be complacent at this stage because it may become a serious health problem again.